While for AML with NPM1 mutation no blast count threshold is defined, the blast count criterion (at least 20 %) still applies to the diagnosis of AML with CEBPA mutation due to insufficient available data as of now [1]. This evidence concerns the gene NPM1 and acute myeloid leukemia.